Ocugen, Inc. (OCGN)
| Market Cap | 561.94M |
| Revenue (ttm) | 4.41M |
| Net Income (ttm) | -67.85M |
| Shares Out | 338.52M |
| EPS (ttm) | -0.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,213,649 |
| Open | 1.710 |
| Previous Close | 1.700 |
| Day's Range | 1.650 - 1.765 |
| 52-Week Range | 0.640 - 2.725 |
| Beta | 2.81 |
| Analysts | Strong Buy |
| Price Target | 9.75 (+487.35%) |
| Earnings Date | May 8, 2026 |
About OCGN
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under ... [Read more]
Financial Performance
In 2025, Ocugen's revenue was $4.41 million, an increase of 8.83% compared to the previous year's $4.06 million. Losses were -$67.85 million, 25.5% more than in 2024.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for OCGN stock is "Strong Buy." The 12-month stock price target is $9.75, which is an increase of 487.35% from the latest price.
News
Ocugen to Present at April 2026 Investor and Industry Conferences
MALVERN, Pa., April 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that D...
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease
MALVERN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that d...
Ocugen Eye Disease Gene Therapy Data Trails Earlier Results, Stocks Falls
OCU410 is an investigational gene therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD).
Ocugen Transcript: Study update
Phase II results for OCU410 in GA showed a 31% reduction in lesion growth at 12 months with a favorable safety profile and significant preservation of photoreceptor structure. The medium dose will advance to phase III, targeting a global enrollment of 300 patients.
Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
MALVERN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced positi...
Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy
MALVERN, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced th...
Ocugen Earnings Call Transcript: Q4 2025
Significant clinical and operational progress was made across gene therapy programs, with key trials advancing and positive data reported. Financial position was strengthened through fundraising and licensing, supporting a cash runway into late 2026 or beyond.
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results
Enrollment for the OCU400 Phase 3 liMeliGhT clinical trial—the first and largest gene therapy registrational trial for broad retinitis pigmentosa patients—was completed. Topline Phase 3 data expected ...
Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa
MALVERN, Pa., March 02, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that e...
Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer
MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the app...
Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock
MALVERN, Pa., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of its previously a...
Ocugen (OCGN) Stock Tumbles After $22.5 Million Share Offering
Ocugen Inc (NASDAQ: OCGN) shares sank sharply on Wednesday after the biotech company announced a $22.5 million underwritten offering of common stock.
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock
MALVERN, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the pricing of its underwritten...
Ocugen's Early Gene Therapy Data Shows 46% Drop In Vision Damage
Ocugen, Inc. (NASDAQ: OCGN) on Thursday shared preliminary data from its phase 2 clinical trial for OCU410, a gene therapy targeting geographic atrophy.
Ocugen Transcript: Study result
OCU410, a one-time gene therapy for geographic atrophy, showed a 46% reduction in lesion growth at 12 months in phase II, with a strong safety profile and up to 50% of patients achieving significant benefit. The therapy targets multiple disease pathways and may offer a durable alternative to chronic injections.
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
MALVERN, Pa., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced positiv...
Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data
MALVERN, Pa., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced tha...
Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy
MALVERN, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the pub...
Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference
MALVERN, Pa., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr...
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
MALVERN, Pa., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr...
Ocugen CEO to Present at NobleCon21—Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference
MALVERN, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr...
Ocugen Earnings Call Transcript: Q3 2025
OCU400 and OCU410ST gene therapy programs advanced toward late-stage regulatory milestones, with strong clinical progress, expanded global partnerships, and a strengthened cash position supporting operations into 2026. Manufacturing and commercialization plans are on track for 2027 launches.
Ocugen Provides Business Update with Third Quarter 2025 Financial Results
Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA) pr...
Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results
MALVERN, Pa., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced tha...
Ocugen Transcript: H.C. Wainwright – Biotech "On Tap" 2025
Three gene therapy programs for major blindness diseases are advancing toward BLA filings between 2026 and 2028, with OCU400 leading in Phase 3 for retinitis pigmentosa. Early clinical data show strong safety and efficacy, and recent financial moves have extended the cash runway into 2027.